AGC Biologics
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions when partnering with our customers in order to help them reach their goals and accelerate their project timelines at our cGMP-compliant facilities. We also partner closely with customers to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Right. On Time.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Research
- Market Focus:
- Globally (various continents)
About Us
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our commitment to continuous innovation fosters the technical creativity to solve our customers’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases. Whatever your need, we will deliver it — Right. On Time.
Mission
To work side by side with our customers in order to improve patients’ lives by bringing new biopharmaceuticals to market.
Vision
To be the first provider that customers call when they are looking for a Contract Development Manufacturing Organization.
Our Values
- Innovation & Operational Excellence
- Diversity
- Protect the Environment
- Integrity
History
In December 2016, CMC Biologics announced that all of its shares were being acquired by AGC Asahi Glass (AGC), a Japanese-based manufacturer of glass, chemicals and high-tech materials.
AGC Biologics was founded in January 2018 in Bothell, Washington, U.S.A., as a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH (Heidelberg, Germany), and CMC Biologics to form a global CDMO focused on offering microbial and mammalian capabilities, fulfilling early-phase through late-phase projects and into routine commercial production, both at small and large-scale.
AGC Biologics has since acquired additional facilities and companies around the world, expanding its offerings and creating a strong global network of manufacturing sites stretching across three continents.
Today, the company provides world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.
The AGC Biologics global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Bothell, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan.
Facilities
We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan.
